Home / Information / NICE
NICE
We are recognised by NICE as an organisation to be consulted on new ALK-positive treatments.
Be empowered with ALK+ lung cancer information you can rely on
ALK Positive UK is committed to producing reliable, accurate and up to date content reflecting the best available research evidence, and best clinical practice. We aim to provide unbiased information free from any commercial conflicts of interest.
Documents
Name
Summary of Contents
Action
Alectinib for adjuvant treatment at Stages 1B - 3A
(November 2024 in Engalnd and April 2025 in Scotland)
This document contains information on Alectinib for use after surgery for early stage ALK-positive LC
Alectinib Aug 2018 (first line)
This document contains information on Alectinib for untreated ALK-positive Non-small cell lung cancer
Brigatinib (after Cerit/Alect)
This webpage contains information on Brigatinib for treating ALK-positive NSCLC after Alectinib/Ceritinib
Brigatinib March 2019 (after Crizotinib)
This document contains information on Brigatinib for treating ALK-positive NSCLC after Ceritinib
Brigatinib Nov 2020 (first line)
This webpage summarises Brigatinib for ALk-positive Advanced NSCLC that hasn't been treated with an ALK Inhibitor
Ceritinib Jan 2018 (first line)
This document contains information on Ceritinib for untreated ALK-positive Non-small cell lung cancer
Ceritinib Jun 2018 (after Crizotinib)
This document contains information on Ceritinib for previously treated ALK-positive Non-small cell lung cancer
Crizotinib Dec 2016 (previously treated)
This document contains information on Crizotinib for previously treated ALK-positive Advanced NSCLC
Crizotinib Sept 2016 (first line)
This document contains information on Crizotinib for untreated ALK-positive Advanced NSCLC
Lorlatinib May 2020 (previously treated)
This document contains information on Lorlatinib for previously treated ALK-positive Advanced NSCLC
Lorlatinib Approved For 1st Line Use in Scotland (March 2022)
This webpage by Healthcare Improvement Scotland contains information on Lorlatinib being accepted for use within NHSScotland
Cancer Recognition & Referral
This document contains information on recognition and referral of suspected cancer
Lung Cancer: Diagnosis and Treatment
This guideline covers diagnosing and managing non-small-cell and small-cell lung cancer.
TKI | Approved | Use |
|---|---|---|
Crizotinib | Sept 2016 | First Line |
Crizotinib | Dec 2016 | After Chemotherapy |
Ceritinib | Jan 2018 | First Line |
Ceritinib | June 2018 | After Crizotinib |
Alectinib | Aug 2018 | First Line |
Brigatinib | March 2019 | After Crizotinib |
Lorlatinib | May 2020 | After Previous Treatment with TKI |
Brigatinib | Nov 2020 | First Line |
Lorlatinib | March 2022 | First Line in Scotland |
Alectinib | Nov 2024 in England & April 2025 in Scotland | After surgery at early stage |
